Literature DB >> 30185654

Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury.

Wai Yan Sun1,2, Bo Bai1,2, Cuiting Luo1,2, Kangmin Yang1,2, Dahui Li1,2, Donghai Wu3, Michel Félétou4, Nicole Villeneuve4, Yang Zhou5, Junwei Yang5, Aimin Xu1,2, Paul M Vanhoutte1,2, Yu Wang1,2.   

Abstract

Lipocalin-2 is not only a sensitive biomarker, but it also contributes to the pathogenesis of renal injuries. The present study demonstrates that adipose tissue-derived lipocalin-2 plays a critical role in causing both chronic and acute renal injuries. Four-week treatment with aldosterone and high salt after uninephrectomy (ANS) significantly increased both circulating and urinary lipocalin-2, and it induced glomerular and tubular injuries in kidneys of WT mice. Despite increased renal expression of lcn2 and urinary excretion of lipocalin-2, mice with selective deletion of lcn2 alleles in adipose tissue (Adipo-LKO) are protected from ANS- or aldosterone-induced renal injuries. By contrast, selective deletion of lcn2 alleles in kidney did not prevent aldosterone- or ANS-induced renal injuries. Transplantation of fat pads from WT donors increased the sensitivity of mice with complete deletion of Lcn2 alleles (LKO) to aldosterone-induced renal injuries. Aldosterone promoted the urinary excretion of a human lipocalin-2 variant, R81E, in turn causing renal injuries in LKO mice. Chronic treatment with R81E triggered significant renal injuries in LKO, resembling those observed in WT mice following ANS challenge. Taken in conjunction, the present results demonstrate that lipocalin-2 derived from adipose tissue causes acute and chronic renal injuries, largely independent of local lcn2 expression in kidney.

Entities:  

Keywords:  Adipose tissue; Inflammation; Mouse models; Nephrology

Mesh:

Substances:

Year:  2018        PMID: 30185654      PMCID: PMC6171815          DOI: 10.1172/jci.insight.120196

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  89 in total

1.  Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.

Authors:  Amandine Viau; Khalil El Karoui; Denise Laouari; Martine Burtin; Clément Nguyen; Kiyoshi Mori; Evangéline Pillebout; Thorsten Berger; Tak Wah Mak; Bertrand Knebelmann; Gérard Friedlander; Jonathan Barasch; Fabiola Terzi
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

Review 2.  Aldosterone blockade in chronic kidney disease: can it improve outcome?

Authors:  Robert D Toto
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

3.  A conserved disulfide motif in human tear lipocalins influences ligand binding.

Authors:  B J Glasgow; A R Abduragimov; T N Yusifov; O K Gasymov; J Horwitz; W L Hubbell; K F Faull
Journal:  Biochemistry       Date:  1998-02-24       Impact factor: 3.162

4.  Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue.

Authors:  María Valero-Muñoz; Shanpeng Li; Richard M Wilson; Maarten Hulsmans; Tamar Aprahamian; José J Fuster; Matthias Nahrendorf; Philipp E Scherer; Flora Sam
Journal:  Circ Heart Fail       Date:  2016-01       Impact factor: 8.790

Review 5.  The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

Authors:  Giuseppe Remuzzi; Norberto Perico; Manuel Macia; Piero Ruggenenti
Journal:  Kidney Int Suppl       Date:  2005-12       Impact factor: 10.545

6.  An iron delivery pathway mediated by a lipocalin.

Authors:  Jun Yang; David Goetz; Jau Yi Li; Wenge Wang; Kiyoshi Mori; Daria Setlik; Tonggong Du; Hediye Erdjument-Bromage; Paul Tempst; Roland Strong; Jonathan Barasch
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

7.  Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes.

Authors:  D Kraus; J Jäger; B Meier; M Fasshauer; J Klein
Journal:  Horm Metab Res       Date:  2005-07       Impact factor: 2.936

8.  Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase.

Authors:  L Kjeldsen; A H Johnsen; H Sengeløv; N Borregaard
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

Review 9.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

10.  Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

Authors:  Murray Epstein; Gordon H Williams; Myron Weinberger; Andrew Lewin; Scott Krause; Robin Mukherjee; Rajiv Patni; Bruce Beckerman
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-19       Impact factor: 8.237

View more
  10 in total

1.  Serum Lipocalin 2 (Neutrophil Gelatinase-Associated Lipocalin) in Relation to Biomarkers of Inflammation and Cardiac Stretch During Activation of the Renin-Angiotensin-Aldosterone System in Human Immunodeficiency Virus.

Authors:  Milana Bogorodskaya; Kathleen V Fitch; Tricia H Burdo; Patrick Maehler; Rebecca M Easly; Gillian R Murray; Meghan Feldpausch; Gail K Adler; Steven K Grinspoon; Suman Srinivasa
Journal:  J Infect Dis       Date:  2019-09-26       Impact factor: 5.226

2.  Single-Cell Profiling of AKI in a Murine Model Reveals Novel Transcriptional Signatures, Profibrotic Phenotype, and Epithelial-to-Stromal Crosstalk.

Authors:  Valeria Rudman-Melnick; Mike Adam; Andrew Potter; Saagar M Chokshi; Qing Ma; Keri A Drake; Meredith P Schuh; J Matthew Kofron; Prasad Devarajan; S Steven Potter
Journal:  J Am Soc Nephrol       Date:  2020-10-28       Impact factor: 10.121

3.  Sex-specific metabolic functions of adipose Lipocalin-2.

Authors:  Karthickeyan Chella Krishnan; Simon Sabir; Michaël Shum; Yonghong Meng; Rebeca Acín-Pérez; Jennifer M Lang; Raquel R Floyd; Laurent Vergnes; Marcus M Seldin; Brie K Fuqua; Dulshan W Jayasekera; Sereena K Nand; Diana C Anum; Calvin Pan; Linsey Stiles; Miklós Péterfy; Karen Reue; Marc Liesa; Aldons J Lusis
Journal:  Mol Metab       Date:  2019-09-27       Impact factor: 7.422

4.  Lipocalin-2 Variants and Their Relationship With Cardio-Renal Risk Factors.

Authors:  Dahui Li; Haoyun Li; Carlie Bauer; Yue Hu; Joshua R Lewis; Aimin Xu; Itamar Levinger; Yu Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-06       Impact factor: 5.555

5.  Serum Alpha-1-Acid Glycoprotein-1 and Urinary Extracellular Vesicle miR-21-5p as Potential Biomarkers of Primary Aldosteronism.

Authors:  Cristian A Carvajal; Alejandra Tapia-Castillo; Jorge A Pérez; Carlos E Fardella
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

Review 6.  Lipocalin 2 Participates in the Epidermal Differentiation and Inflammatory Processes of Psoriasis.

Authors:  Kaixuan Ren; Yumin Xia
Journal:  J Inflamm Res       Date:  2022-03-31

7.  Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury.

Authors:  Toshifumi Nakamura; Benjamin Bonnard; Roberto Palacios-Ramirez; Amaya Fernández-Celis; Frédéric Jaisser; Natalia López-Andrés
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

Review 8.  Mechanisms of Post-critical Illness Cardiovascular Disease.

Authors:  Andrew Owen; Jaimin M Patel; Dhruv Parekh; Mansoor N Bangash
Journal:  Front Cardiovasc Med       Date:  2022-07-15

Review 9.  Roles of bone-derived hormones in type 2 diabetes and cardiovascular pathophysiology.

Authors:  Xuzhu Lin; Danise-Ann Onda; Chieh-Hsin Yang; Joshua R Lewis; Itamar Levinger; Kim Loh
Journal:  Mol Metab       Date:  2020-06-13       Impact factor: 7.422

10.  A Mixture of Pure, Isolated Polyphenols Worsens the Insulin Resistance and Induces Kidney and Liver Fibrosis Markers in Diet-Induced Obese Mice.

Authors:  Hèctor Sanz-Lamora; Pedro F Marrero; Diego Haro; Joana Relat
Journal:  Antioxidants (Basel)       Date:  2022-01-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.